NDA 218591 · Novartis
Entresto Sprinkle
Sacubitril, Valsartan · Oral · Angiotensin 2 Receptor Blocker
Last checked: Nov 19, 2026Latest source record: Apr 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Apr 12, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
181
44 Phase 3, 23 recruiting
FAERS reports
116,184
59,720 serious, 14,200 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ENTRESTO as soon as possible (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue ENTRESTO as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
What it is approved for
From the label in effect Jul 6, 2026.
ENTRESTO is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure ENTRESTO is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes.
Mechanism: ENTRESTO contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. ENTRESTO inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT 1 ) receptor via valsartan. The cardiovascular and renal effects of ENTRESTO in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- ENTRESTO SPRINKLE · SACUBITRIL 6MG; VALSARTAN 6MG · CAPSULE, PELLETS, ORAL · Prescription
- ENTRESTO SPRINKLE · SACUBITRIL 15MG; VALSARTAN 16MG · CAPSULE, PELLETS, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sacubitril" as an intervention, any sponsor and status, largest first.
- This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailurePivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01035255 · 8,442 participants · Start Dec 2009 · Primary completion May 2014
Drug: LCZ696 200 mg BID; Enalapril 10 mg BID · For: Heart Failure With Reduced Ejection Fraction
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,031 sites in all
- Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MIPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02924727 · 5,669 participants · Start Dec 9, 2016 · Primary completion Feb 26, 2021
Drug: LCZ696 (sacubitril/valsartan); Ramipril and 4 more · For: Acute Myocardial Infarction
Sites: Birmingham, Alabama; Huntsville, Alabama; Gilbert, Arizona · 486 sites in all
- Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01920711 · 4,822 participants · Start Jul 18, 2014 · Primary completion Jun 7, 2019
Drug: LCZ696; Valsartan · For: Heart Failure With Preserved Ejection Fraction
Sites: Huntsville, Alabama; Mobile, Alabama; Muscle Shoals, Alabama · 715 sites in all
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03066804 · 2,572 participants · Start Aug 22, 2017 · Primary completion Oct 28, 2019
Drug: sacubitril/valsartan; Enalapril and 4 more · For: Heart Failure With Preserved Ejection Fraction
Sites: Andalusia, Alabama; Mobile, Alabama; Beverly Hills, California · 380 sites in all
- Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)Pivotal-lookingStatus unknown
Xiangtan Central HospitalAcademic, hospital or other
NCT04707261 · 1,990 participants (planned) · Start Aug 6, 2021 · Primary completion May 5, 2025
Drug: Dapagliflozin; Placebo · For: Anemia; Heart Failure
Sites: Xiangtan, China
- Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection FractionPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02226120 · 1,980 participants · Start Oct 16, 2014 · Primary completion Dec 28, 2017
Drug: LCZ696 · For: Chronic Heart Failure With Reduced Ejection Fraction
Sites: Huntsville, Alabama; Muscle Shoals, Alabama; Little Rock, Arkansas · 394 sites in all
- Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential HypertensionPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01785472 · 1,438 participants · Start Apr 2013 · Primary completion Aug 2014
Drug: LCZ696; Olmesartan and 2 more · For: Essential Hypertension
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 50 sites in all
- Efficacy and Safety of LCZ696A in Patients With Essential HypertensionPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00549770 · 1,334 participants · Start Sep 2007 · Primary completion Jul 2008
Drug: LCZ696; Valsartan and 2 more · For: Hypertension
Sites: Birmingham, Alabama; Muscle Shoals, Alabama; Chandler, Arizona · 182 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypotension11,679
- death9,164
- dyspnoea9,055
- dizziness8,785
- fatigue8,758
- cough7,892
- wrong technique in product usage process7,341
- weight decreased5,230
- cardiac failure4,550
- malaise4,473
- asthenia3,844
- weight increased3,520
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 971 |
| 2016 | 6,442 |
| 2017 | 7,878 |
| 2018 | 12,218 |
| 2019 | 12,941 |
| 2020 | 12,382 |
| 2021 | 16,985 |
| 2022 | 19,265 |
| 2023 | 16,689 |
| 2024 | 4,599 |
| 2025 | 3,594 |
| 2026 | 2,216 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Entresto Sprinkle (Sacubitril/Valsartan)
2024 spending
$145K
Beneficiaries
97
173 claims
Per beneficiary
$1,492
$11.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $144,718 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Anand IS, et al. · N Engl J Med 2019 · Comparative Study, Multicenter Study
- Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.
Shaddy R, Burch M, Kantor PF, et al. · Circulation 2024 · Randomized Controlled Trial, Multicenter Study
- [The PARAGON-HF trial].
Tridetti J, Nguyen Trung ML, Ancion A, et al. · Rev Med Liege 2020 · Multicenter Study, Randomized Controlled Trial
- Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.
Peikert A, Vaduganathan M, Claggett BL, et al. · Eur Heart J 2025 · Randomized Controlled Trial, Multicenter Study
- Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ, Morrow DA, DeVore AD, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Updates in chronic kidney disease management: A systematic review.
Ammar A, Edwin SB, Whitney R, et al. · Pharmacotherapy 2025 · Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.